排序方式: 共有213条查询结果,搜索用时 15 毫秒
211.
212.
tefica Horvat Lidija Varga-Defterdarovi
Jaroslav Horvat Rua Juki Darko Kantoci Nga N. Chung Peter W. Schiller Lothar Biesert Andreas Pfützner Haryadi Suhartono Helga Rübsamen-Waigmann 《Journal of peptide science》1995,1(5):303-310
Small enkephalin-related peptides containing a 1-adamantanamine moiety coupled through an amide linkage at the C-terminus were synthesized. Several of the compounds showed high μ opioid activity and μ receptor selectivity. The new adamantanamine derivatives were also examined for antiviral activity against HIV-1 in a cell culture system. Some of them inhibited syncytia formation even when the antigen assay gave evidence for viral replication. 相似文献
213.
Predrag Sikiric Sven Seiwerth Gorana Aralica Darko Perovic Mario Staresinic Tomislav Anic Miroslav Gjurasin Ingrid Prkacin Jadranka Separovic Dinko Stancic-Rokotov Martina Lovric-Bencic Darko Mikus Branko Turkovic Ivo Rotkvic Stjepan Mise Rudolf Rucman Marijan Petek Tihomil Ziger Bozidar Sebecic Zoran Ivasovic Vjekoslav Jagic Ljiljana Komericki Ivan Balen Alenka Boban-Blagaic Ivo Sjekavica 《Journal of Physiology》2001,95(1-6):283-288
After demonstration that cysteamine induced duodenal lesions in gastrectomized rats, while a number of antiulcer drugs mitigated these lesions, it was shown that one single intrarectal (i.r.) cysteamine application produced severe colon lesions in acute studies in rats. Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats. Regularly, cysteamine colon lesions were markedly mitigated by ranitidine (10), omeprazole (10), atropine (10), methylprednisolone (1), sulphasalazine (50; mg/kg), pentadecapeptide BPC 157 (PL-10, PLD-116; 10 microg or 10 ng/kg). Specifically, after 1 or 3 months following initial challenge (cysteamine 400 mg/kg i.r.) in female rat, the therapy [BPC 157 (PL-10, PLD-116 (10.0 microg or 10.0 ng/kg; i.g., i.p., i.r.), ranitidine, omeprazole, atropine, methylprednisolone, sulphasalazine (i.p.)] reversed the protracted cysteamine colon injury: the 1 week-regimen (once daily application) started after 1 month post-cysteamine, as well as the 2 weeks-regimen (once daily application), which started after 3 months. The effect on recidive lesion was also tested. These cysteamine lesions may reappear after stopping therapy (after stopping therapy for 3 weeks at the end of 2-weeks regimen started in 3 months-cysteamine female rats) in sulphasalazine group, while this reappearance is markedly antagonized in pentadecapeptide BPC 157 (PL-10, PLD-116)-rats (cysteamine-colon lesion still substantially low). 相似文献